Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Cancer Research|July 3, 2004
In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cellsPierfrancesco Tassone, Antonella Gozzini, Victor Goldmacher, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
Scouring the human Hsp70 network uncovers diverse chaperone safeguards buffering TDP-43 toxicityEdward M Barbieri, Miriam Linsenmeier, Katherine R Whiteman, et al.
Annals of Biomedical Engineering|March 17, 2015
Characterisation of Elastic and Acoustic Properties of an Agar-Based Tissue Mimicking MaterialM P Brewin, M J Birch, D J Mehta, et al.
Molecular Cancer Therapeutics|April 24, 2015
IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing TumorsOlga Ab, Kathleen R Whiteman, Laura M Bartle, et al.
Biorxiv : the Preprint Server for Biology|February 14, 2024
AAV-based delivery of RNAi targeting Ataxin-2 improves survival, strength, and pathology in mouse models of rapidly and slowly progressive sporadic ALSDefne A Amado, Ashley B Robbins, Alicia R Smith, et al.
Molecular Cancer Therapeutics|March 29, 2018
IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AMLYelena Kovtun, Paul Noordhuis, Kathleen R Whiteman, et al.
Bioconjugate Chemistry|March 24, 2011
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkageBrenda A Kellogg, Lisa Garrett, Yelena Kovtun, et al.
Journal of Medicinal Chemistry|July 11, 2006
Semisynthetic maytansine analogues for the targeted treatment of cancerWayne C Widdison, Sharon D Wilhelm, Emily E Cavanagh, et al.
Plos One|May 4, 2022
BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activityTaylor L Hickman, Eugene Choi, Kathleen R Whiteman, et al.
Molecular Pharmaceutics|July 10, 2019
A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine ConjugationNicholas C Yoder, Chen Bai, Daniel Tavares, et al.
Pageof 4